nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP2D6—Fingolimod—multiple sclerosis	0.0391	0.189	CbGbCtD
Ziprasidone—HTR1B—trigeminal nucleus—multiple sclerosis	0.0278	0.115	CbGeAlD
Ziprasidone—HTR1D—trigeminal nucleus—multiple sclerosis	0.027	0.111	CbGeAlD
Ziprasidone—CYP3A4—Fingolimod—multiple sclerosis	0.0249	0.12	CbGbCtD
Ziprasidone—HTR3A—area postrema—multiple sclerosis	0.0245	0.101	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0207	0.1	CbGbCtD
Ziprasidone—CYP3A7—Dexamethasone—multiple sclerosis	0.0207	0.1	CbGbCtD
Ziprasidone—HTR1D—meninx—multiple sclerosis	0.0179	0.0739	CbGeAlD
Ziprasidone—CYP3A4—Methylprednisolone—multiple sclerosis	0.016	0.0775	CbGbCtD
Ziprasidone—CYP3A5—Dexamethasone—multiple sclerosis	0.0156	0.0751	CbGbCtD
Ziprasidone—HTR2A—trigeminal nucleus—multiple sclerosis	0.0134	0.0553	CbGeAlD
Ziprasidone—CYP3A4—Triamcinolone—multiple sclerosis	0.0122	0.0587	CbGbCtD
Ziprasidone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0117	0.0565	CbGbCtD
Ziprasidone—CYP3A4—Betamethasone—multiple sclerosis	0.0104	0.0504	CbGbCtD
Ziprasidone—CYP3A4—Prednisolone—multiple sclerosis	0.0103	0.0497	CbGbCtD
Ziprasidone—CYP3A4—Prednisone—multiple sclerosis	0.00972	0.0469	CbGbCtD
Ziprasidone—CYP2D6—Dexamethasone—multiple sclerosis	0.00954	0.0461	CbGbCtD
Ziprasidone—HTR1B—trigeminal nerve—multiple sclerosis	0.00731	0.0302	CbGeAlD
Ziprasidone—HTR1D—trigeminal nerve—multiple sclerosis	0.00708	0.0292	CbGeAlD
Ziprasidone—CYP3A4—Dexamethasone—multiple sclerosis	0.00607	0.0293	CbGbCtD
Ziprasidone—HTR7—pons—multiple sclerosis	0.00397	0.0164	CbGeAlD
Ziprasidone—HTR2A—trigeminal nerve—multiple sclerosis	0.00352	0.0145	CbGeAlD
Ziprasidone—DRD1—nerve—multiple sclerosis	0.0033	0.0136	CbGeAlD
Ziprasidone—HTR3A—nerve—multiple sclerosis	0.00318	0.0131	CbGeAlD
Ziprasidone—HTR7—peripheral nervous system—multiple sclerosis	0.00264	0.0109	CbGeAlD
Ziprasidone—HTR2A—pons—multiple sclerosis	0.00248	0.0102	CbGeAlD
Ziprasidone—HTR1E—brainstem—multiple sclerosis	0.00242	0.01	CbGeAlD
Ziprasidone—HTR7—nerve—multiple sclerosis	0.00206	0.0085	CbGeAlD
Ziprasidone—DRD2—nerve—multiple sclerosis	0.00195	0.00804	CbGeAlD
Ziprasidone—ADRA2A—peripheral nervous system—multiple sclerosis	0.00194	0.008	CbGeAlD
Ziprasidone—HTR2A—pineal body—multiple sclerosis	0.00177	0.0073	CbGeAlD
Ziprasidone—HTR2A—peripheral nervous system—multiple sclerosis	0.00165	0.0068	CbGeAlD
Ziprasidone—DRD1—brainstem—multiple sclerosis	0.00142	0.00584	CbGeAlD
Ziprasidone—H1F0—retina—multiple sclerosis	0.00138	0.00571	CbGeAlD
Ziprasidone—HTR3A—brainstem—multiple sclerosis	0.00137	0.00564	CbGeAlD
Ziprasidone—HTR2A—nerve—multiple sclerosis	0.00128	0.0053	CbGeAlD
Ziprasidone—HTR1E—nervous system—multiple sclerosis	0.00127	0.00524	CbGeAlD
Ziprasidone—HTR1E—central nervous system—multiple sclerosis	0.00122	0.00505	CbGeAlD
Ziprasidone—HTR1B—brainstem—multiple sclerosis	0.00115	0.00473	CbGeAlD
Ziprasidone—DRD4—brain—multiple sclerosis	0.00113	0.00465	CbGeAlD
Ziprasidone—CHRM4—nervous system—multiple sclerosis	0.00111	0.0046	CbGeAlD
Ziprasidone—HTR1D—brainstem—multiple sclerosis	0.00111	0.00458	CbGeAlD
Ziprasidone—HTR2C—brainstem—multiple sclerosis	0.0011	0.00454	CbGeAlD
Ziprasidone—CHRM4—central nervous system—multiple sclerosis	0.00107	0.00443	CbGeAlD
Ziprasidone—SLC6A4—brainstem—multiple sclerosis	0.00104	0.0043	CbGeAlD
Ziprasidone—DRD3—nervous system—multiple sclerosis	0.00104	0.00427	CbGeAlD
Ziprasidone—H1F0—medulla oblongata—multiple sclerosis	0.000999	0.00412	CbGeAlD
Ziprasidone—DRD3—central nervous system—multiple sclerosis	0.000997	0.00411	CbGeAlD
Ziprasidone—HTR6—nervous system—multiple sclerosis	0.000997	0.00411	CbGeAlD
Ziprasidone—HTR1E—brain—multiple sclerosis	0.000971	0.00401	CbGeAlD
Ziprasidone—DRD5—nervous system—multiple sclerosis	0.00097	0.00401	CbGeAlD
Ziprasidone—HTR6—central nervous system—multiple sclerosis	0.00096	0.00396	CbGeAlD
Ziprasidone—DRD5—central nervous system—multiple sclerosis	0.000934	0.00386	CbGeAlD
Ziprasidone—HTR1A—brainstem—multiple sclerosis	0.000925	0.00382	CbGeAlD
Ziprasidone—H1F0—midbrain—multiple sclerosis	0.000913	0.00377	CbGeAlD
Ziprasidone—DRD1—midbrain—multiple sclerosis	0.000902	0.00372	CbGeAlD
Ziprasidone—H1F0—spinal cord—multiple sclerosis	0.000891	0.00368	CbGeAlD
Ziprasidone—HTR7—brainstem—multiple sclerosis	0.000884	0.00365	CbGeAlD
Ziprasidone—CHRM5—nervous system—multiple sclerosis	0.000871	0.00359	CbGeAlD
Ziprasidone—ADRA1A—brainstem—multiple sclerosis	0.000853	0.00352	CbGeAlD
Ziprasidone—CHRM4—brain—multiple sclerosis	0.000851	0.00351	CbGeAlD
Ziprasidone—CHRM5—central nervous system—multiple sclerosis	0.000838	0.00346	CbGeAlD
Ziprasidone—DRD2—brainstem—multiple sclerosis	0.000836	0.00345	CbGeAlD
Ziprasidone—DRD2—retina—multiple sclerosis	0.000807	0.00333	CbGeAlD
Ziprasidone—ADRA1B—nervous system—multiple sclerosis	0.000795	0.00328	CbGeAlD
Ziprasidone—DRD3—brain—multiple sclerosis	0.000791	0.00327	CbGeAlD
Ziprasidone—HTR2C—medulla oblongata—multiple sclerosis	0.000767	0.00316	CbGeAlD
Ziprasidone—ADRA1B—central nervous system—multiple sclerosis	0.000766	0.00316	CbGeAlD
Ziprasidone—HTR6—brain—multiple sclerosis	0.000762	0.00314	CbGeAlD
Ziprasidone—H1F0—nervous system—multiple sclerosis	0.000751	0.0031	CbGeAlD
Ziprasidone—DRD5—brain—multiple sclerosis	0.000742	0.00306	CbGeAlD
Ziprasidone—DRD1—nervous system—multiple sclerosis	0.000741	0.00306	CbGeAlD
Ziprasidone—HTR1B—midbrain—multiple sclerosis	0.000731	0.00302	CbGeAlD
Ziprasidone—H1F0—central nervous system—multiple sclerosis	0.000723	0.00298	CbGeAlD
Ziprasidone—HTR3A—nervous system—multiple sclerosis	0.000716	0.00296	CbGeAlD
Ziprasidone—DRD1—central nervous system—multiple sclerosis	0.000714	0.00295	CbGeAlD
Ziprasidone—HTR1B—spinal cord—multiple sclerosis	0.000713	0.00294	CbGeAlD
Ziprasidone—HTR1D—midbrain—multiple sclerosis	0.000708	0.00292	CbGeAlD
Ziprasidone—H1F0—cerebellum—multiple sclerosis	0.000707	0.00292	CbGeAlD
Ziprasidone—HTR2C—midbrain—multiple sclerosis	0.000701	0.00289	CbGeAlD
Ziprasidone—HTR3A—central nervous system—multiple sclerosis	0.000689	0.00285	CbGeAlD
Ziprasidone—HTR2C—spinal cord—multiple sclerosis	0.000684	0.00282	CbGeAlD
Ziprasidone—CHRM5—brain—multiple sclerosis	0.000665	0.00275	CbGeAlD
Ziprasidone—SLC6A4—midbrain—multiple sclerosis	0.000664	0.00274	CbGeAlD
Ziprasidone—SLC6A4—spinal cord—multiple sclerosis	0.000648	0.00267	CbGeAlD
Ziprasidone—HTR7—medulla oblongata—multiple sclerosis	0.000617	0.00255	CbGeAlD
Ziprasidone—ADRA1B—brain—multiple sclerosis	0.000608	0.00251	CbGeAlD
Ziprasidone—HTR1B—nervous system—multiple sclerosis	0.000601	0.00248	CbGeAlD
Ziprasidone—CHRM2—nervous system—multiple sclerosis	0.000598	0.00247	CbGeAlD
Ziprasidone—HTR1A—midbrain—multiple sclerosis	0.00059	0.00243	CbGeAlD
Ziprasidone—HTR1D—nervous system—multiple sclerosis	0.000582	0.0024	CbGeAlD
Ziprasidone—HTR1B—central nervous system—multiple sclerosis	0.000578	0.00239	CbGeAlD
Ziprasidone—HTR2C—nervous system—multiple sclerosis	0.000576	0.00238	CbGeAlD
Ziprasidone—HTR1A—spinal cord—multiple sclerosis	0.000575	0.00237	CbGeAlD
Ziprasidone—CHRM2—central nervous system—multiple sclerosis	0.000575	0.00237	CbGeAlD
Ziprasidone—KCNH2—medulla oblongata—multiple sclerosis	0.000574	0.00237	CbGeAlD
Ziprasidone—H1F0—brain—multiple sclerosis	0.000574	0.00237	CbGeAlD
Ziprasidone—ADRA2C—medulla oblongata—multiple sclerosis	0.000567	0.00234	CbGeAlD
Ziprasidone—DRD1—brain—multiple sclerosis	0.000567	0.00234	CbGeAlD
Ziprasidone—HTR7—midbrain—multiple sclerosis	0.000564	0.00233	CbGeAlD
Ziprasidone—HTR1D—central nervous system—multiple sclerosis	0.00056	0.00231	CbGeAlD
Ziprasidone—HTR2C—central nervous system—multiple sclerosis	0.000555	0.00229	CbGeAlD
Ziprasidone—HTR2A—brainstem—multiple sclerosis	0.000551	0.00228	CbGeAlD
Ziprasidone—HTR7—spinal cord—multiple sclerosis	0.00055	0.00227	CbGeAlD
Ziprasidone—HTR3A—brain—multiple sclerosis	0.000547	0.00226	CbGeAlD
Ziprasidone—SLC6A4—nervous system—multiple sclerosis	0.000546	0.00225	CbGeAlD
Ziprasidone—CHRM1—nervous system—multiple sclerosis	0.000544	0.00225	CbGeAlD
Ziprasidone—DRD2—midbrain—multiple sclerosis	0.000533	0.0022	CbGeAlD
Ziprasidone—HTR2A—retina—multiple sclerosis	0.000532	0.0022	CbGeAlD
Ziprasidone—SLC6A4—central nervous system—multiple sclerosis	0.000526	0.00217	CbGeAlD
Ziprasidone—KCNH2—midbrain—multiple sclerosis	0.000525	0.00217	CbGeAlD
Ziprasidone—CHRM1—central nervous system—multiple sclerosis	0.000524	0.00216	CbGeAlD
Ziprasidone—ADRA2C—midbrain—multiple sclerosis	0.000518	0.00214	CbGeAlD
Ziprasidone—KCNH2—spinal cord—multiple sclerosis	0.000512	0.00211	CbGeAlD
Ziprasidone—ADRA2C—spinal cord—multiple sclerosis	0.000505	0.00209	CbGeAlD
Ziprasidone—CYP2D6—brainstem—multiple sclerosis	0.000502	0.00207	CbGeAlD
Ziprasidone—CHRM3—nervous system—multiple sclerosis	0.000487	0.00201	CbGeAlD
Ziprasidone—HTR1A—nervous system—multiple sclerosis	0.000485	0.002	CbGeAlD
Ziprasidone—CHRM3—central nervous system—multiple sclerosis	0.000469	0.00193	CbGeAlD
Ziprasidone—HTR1A—central nervous system—multiple sclerosis	0.000467	0.00193	CbGeAlD
Ziprasidone—HTR7—nervous system—multiple sclerosis	0.000463	0.00191	CbGeAlD
Ziprasidone—HTR1B—brain—multiple sclerosis	0.000459	0.0019	CbGeAlD
Ziprasidone—CHRM2—brain—multiple sclerosis	0.000457	0.00189	CbGeAlD
Ziprasidone—HTR1A—cerebellum—multiple sclerosis	0.000456	0.00188	CbGeAlD
Ziprasidone—ADRA2A—medulla oblongata—multiple sclerosis	0.000452	0.00187	CbGeAlD
Ziprasidone—ADRA1A—nervous system—multiple sclerosis	0.000447	0.00184	CbGeAlD
Ziprasidone—HTR7—central nervous system—multiple sclerosis	0.000446	0.00184	CbGeAlD
Ziprasidone—HTR1D—brain—multiple sclerosis	0.000445	0.00184	CbGeAlD
Ziprasidone—HTR2C—brain—multiple sclerosis	0.00044	0.00182	CbGeAlD
Ziprasidone—DRD2—nervous system—multiple sclerosis	0.000438	0.00181	CbGeAlD
Ziprasidone—HTR7—cerebellum—multiple sclerosis	0.000436	0.0018	CbGeAlD
Ziprasidone—KCNH2—nervous system—multiple sclerosis	0.000432	0.00178	CbGeAlD
Ziprasidone—ADRA1A—central nervous system—multiple sclerosis	0.00043	0.00178	CbGeAlD
Ziprasidone—ADRA2C—nervous system—multiple sclerosis	0.000426	0.00176	CbGeAlD
Ziprasidone—DRD2—central nervous system—multiple sclerosis	0.000422	0.00174	CbGeAlD
Ziprasidone—ADRA1A—cerebellum—multiple sclerosis	0.000421	0.00174	CbGeAlD
Ziprasidone—SLC6A4—brain—multiple sclerosis	0.000417	0.00172	CbGeAlD
Ziprasidone—CHRM1—brain—multiple sclerosis	0.000416	0.00172	CbGeAlD
Ziprasidone—KCNH2—central nervous system—multiple sclerosis	0.000416	0.00172	CbGeAlD
Ziprasidone—ADRA2A—midbrain—multiple sclerosis	0.000413	0.00171	CbGeAlD
Ziprasidone—DRD2—cerebellum—multiple sclerosis	0.000412	0.0017	CbGeAlD
Ziprasidone—ADRA2C—central nervous system—multiple sclerosis	0.00041	0.00169	CbGeAlD
Ziprasidone—KCNH2—cerebellum—multiple sclerosis	0.000406	0.00168	CbGeAlD
Ziprasidone—ADRA2A—spinal cord—multiple sclerosis	0.000403	0.00166	CbGeAlD
Ziprasidone—ADRA2C—cerebellum—multiple sclerosis	0.000401	0.00165	CbGeAlD
Ziprasidone—HTR2A—medulla oblongata—multiple sclerosis	0.000385	0.00159	CbGeAlD
Ziprasidone—CHRM3—brain—multiple sclerosis	0.000372	0.00154	CbGeAlD
Ziprasidone—HTR1A—brain—multiple sclerosis	0.000371	0.00153	CbGeAlD
Ziprasidone—HTR7—brain—multiple sclerosis	0.000354	0.00146	CbGeAlD
Ziprasidone—HTR2A—midbrain—multiple sclerosis	0.000351	0.00145	CbGeAlD
Ziprasidone—HRH1—nervous system—multiple sclerosis	0.000346	0.00143	CbGeAlD
Ziprasidone—HTR2A—spinal cord—multiple sclerosis	0.000343	0.00142	CbGeAlD
Ziprasidone—ADRA1A—brain—multiple sclerosis	0.000342	0.00141	CbGeAlD
Ziprasidone—ADRA2A—nervous system—multiple sclerosis	0.00034	0.0014	CbGeAlD
Ziprasidone—DRD2—brain—multiple sclerosis	0.000335	0.00138	CbGeAlD
Ziprasidone—HRH1—central nervous system—multiple sclerosis	0.000333	0.00137	CbGeAlD
Ziprasidone—KCNH2—brain—multiple sclerosis	0.00033	0.00136	CbGeAlD
Ziprasidone—ADRA2A—central nervous system—multiple sclerosis	0.000327	0.00135	CbGeAlD
Ziprasidone—ADRA2C—brain—multiple sclerosis	0.000326	0.00134	CbGeAlD
Ziprasidone—ADRA2A—cerebellum—multiple sclerosis	0.00032	0.00132	CbGeAlD
Ziprasidone—HTR2A—nervous system—multiple sclerosis	0.000289	0.00119	CbGeAlD
Ziprasidone—HTR2A—central nervous system—multiple sclerosis	0.000278	0.00115	CbGeAlD
Ziprasidone—HTR2A—cerebellum—multiple sclerosis	0.000272	0.00112	CbGeAlD
Ziprasidone—CYP3A4—nervous system—multiple sclerosis	0.000267	0.0011	CbGeAlD
Ziprasidone—HRH1—brain—multiple sclerosis	0.000264	0.00109	CbGeAlD
Ziprasidone—CYP2D6—nervous system—multiple sclerosis	0.000263	0.00109	CbGeAlD
Ziprasidone—ADRA2A—brain—multiple sclerosis	0.00026	0.00107	CbGeAlD
Ziprasidone—CYP3A4—central nervous system—multiple sclerosis	0.000258	0.00106	CbGeAlD
Ziprasidone—CYP2D6—central nervous system—multiple sclerosis	0.000253	0.00105	CbGeAlD
Ziprasidone—CYP2D6—cerebellum—multiple sclerosis	0.000248	0.00102	CbGeAlD
Ziprasidone—HTR2A—brain—multiple sclerosis	0.000221	0.000912	CbGeAlD
Ziprasidone—Dermatitis—Azathioprine—multiple sclerosis	0.000201	0.000604	CcSEcCtD
Ziprasidone—CYP2D6—brain—multiple sclerosis	0.000201	0.00083	CbGeAlD
Ziprasidone—Headache—Azathioprine—multiple sclerosis	0.0002	0.0006	CcSEcCtD
Ziprasidone—Dry mouth—Triamcinolone—multiple sclerosis	0.000199	0.000596	CcSEcCtD
Ziprasidone—Renal failure—Methotrexate—multiple sclerosis	0.000198	0.000595	CcSEcCtD
Ziprasidone—Angioedema—Dexamethasone—multiple sclerosis	0.000198	0.000594	CcSEcCtD
Ziprasidone—Angioedema—Betamethasone—multiple sclerosis	0.000198	0.000594	CcSEcCtD
Ziprasidone—Angiopathy—Prednisone—multiple sclerosis	0.000197	0.00059	CcSEcCtD
Ziprasidone—Conjunctivitis—Methotrexate—multiple sclerosis	0.000196	0.000588	CcSEcCtD
Ziprasidone—Confusional state—Methylprednisolone—multiple sclerosis	0.000196	0.000588	CcSEcCtD
Ziprasidone—Immune system disorder—Prednisone—multiple sclerosis	0.000196	0.000587	CcSEcCtD
Ziprasidone—Vertigo—Betamethasone—multiple sclerosis	0.000195	0.000584	CcSEcCtD
Ziprasidone—Vertigo—Dexamethasone—multiple sclerosis	0.000195	0.000584	CcSEcCtD
Ziprasidone—Syncope—Betamethasone—multiple sclerosis	0.000194	0.000583	CcSEcCtD
Ziprasidone—Syncope—Dexamethasone—multiple sclerosis	0.000194	0.000583	CcSEcCtD
Ziprasidone—Arrhythmia—Prednisone—multiple sclerosis	0.000194	0.000581	CcSEcCtD
Ziprasidone—Infection—Triamcinolone—multiple sclerosis	0.000194	0.000581	CcSEcCtD
Ziprasidone—Sweating—Methotrexate—multiple sclerosis	0.000193	0.00058	CcSEcCtD
Ziprasidone—Infection—Methylprednisolone—multiple sclerosis	0.000193	0.000579	CcSEcCtD
Ziprasidone—Haematuria—Methotrexate—multiple sclerosis	0.000192	0.000577	CcSEcCtD
Ziprasidone—Shock—Triamcinolone—multiple sclerosis	0.000192	0.000575	CcSEcCtD
Ziprasidone—Insomnia—Prednisolone—multiple sclerosis	0.000192	0.000575	CcSEcCtD
Ziprasidone—Alopecia—Prednisone—multiple sclerosis	0.000192	0.000574	CcSEcCtD
Ziprasidone—Shock—Methylprednisolone—multiple sclerosis	0.000191	0.000574	CcSEcCtD
Ziprasidone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000191	0.000572	CcSEcCtD
Ziprasidone—Loss of consciousness—Betamethasone—multiple sclerosis	0.00019	0.000571	CcSEcCtD
Ziprasidone—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00019	0.000571	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—multiple sclerosis	0.00019	0.000571	CcSEcCtD
Ziprasidone—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00019	0.000571	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisolone—multiple sclerosis	0.00019	0.000571	CcSEcCtD
Ziprasidone—Tachycardia—Triamcinolone—multiple sclerosis	0.00019	0.00057	CcSEcCtD
Ziprasidone—Mental disorder—Prednisone—multiple sclerosis	0.00019	0.000569	CcSEcCtD
Ziprasidone—Nausea—Azathioprine—multiple sclerosis	0.00019	0.000569	CcSEcCtD
Ziprasidone—Tachycardia—Methylprednisolone—multiple sclerosis	0.00019	0.000569	CcSEcCtD
Ziprasidone—Skin disorder—Methylprednisolone—multiple sclerosis	0.000189	0.000566	CcSEcCtD
Ziprasidone—Erythema—Prednisone—multiple sclerosis	0.000189	0.000566	CcSEcCtD
Ziprasidone—Malnutrition—Prednisone—multiple sclerosis	0.000189	0.000566	CcSEcCtD
Ziprasidone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000188	0.000565	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000188	0.000564	CcSEcCtD
Ziprasidone—Hypertension—Dexamethasone—multiple sclerosis	0.000187	0.000561	CcSEcCtD
Ziprasidone—Hypertension—Betamethasone—multiple sclerosis	0.000187	0.000561	CcSEcCtD
Ziprasidone—Asthenia—Mitoxantrone—multiple sclerosis	0.000185	0.000556	CcSEcCtD
Ziprasidone—Myalgia—Betamethasone—multiple sclerosis	0.000184	0.000553	CcSEcCtD
Ziprasidone—Myalgia—Dexamethasone—multiple sclerosis	0.000184	0.000553	CcSEcCtD
Ziprasidone—Anxiety—Betamethasone—multiple sclerosis	0.000184	0.000551	CcSEcCtD
Ziprasidone—Anxiety—Dexamethasone—multiple sclerosis	0.000184	0.000551	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—multiple sclerosis	0.000182	0.000546	CcSEcCtD
Ziprasidone—Hypotension—Methylprednisolone—multiple sclerosis	0.000182	0.000545	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—multiple sclerosis	0.000181	0.000543	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—multiple sclerosis	0.000181	0.000543	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—multiple sclerosis	0.00018	0.000539	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000179	0.000536	CcSEcCtD
Ziprasidone—Vision blurred—Prednisone—multiple sclerosis	0.000178	0.000533	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—multiple sclerosis	0.000178	0.000533	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000178	0.000532	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000177	0.000531	CcSEcCtD
Ziprasidone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000177	0.00053	CcSEcCtD
Ziprasidone—Insomnia—Triamcinolone—multiple sclerosis	0.000176	0.000529	CcSEcCtD
Ziprasidone—Insomnia—Methylprednisolone—multiple sclerosis	0.000176	0.000527	CcSEcCtD
Ziprasidone—Infection—Betamethasone—multiple sclerosis	0.000176	0.000527	CcSEcCtD
Ziprasidone—Infection—Dexamethasone—multiple sclerosis	0.000176	0.000527	CcSEcCtD
Ziprasidone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000175	0.000525	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000175	0.000524	CcSEcCtD
Ziprasidone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000175	0.000524	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—multiple sclerosis	0.000175	0.000524	CcSEcCtD
Ziprasidone—Anaemia—Prednisone—multiple sclerosis	0.000174	0.000523	CcSEcCtD
Ziprasidone—Shock—Dexamethasone—multiple sclerosis	0.000174	0.000522	CcSEcCtD
Ziprasidone—Shock—Betamethasone—multiple sclerosis	0.000174	0.000522	CcSEcCtD
Ziprasidone—Dyspnoea—Triamcinolone—multiple sclerosis	0.000174	0.000521	CcSEcCtD
Ziprasidone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000173	0.00052	CcSEcCtD
Ziprasidone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000173	0.00052	CcSEcCtD
Ziprasidone—Agitation—Prednisone—multiple sclerosis	0.000173	0.00052	CcSEcCtD
Ziprasidone—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000173	0.000519	CcSEcCtD
Ziprasidone—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000173	0.000519	CcSEcCtD
Ziprasidone—Tachycardia—Betamethasone—multiple sclerosis	0.000173	0.000518	CcSEcCtD
Ziprasidone—Tachycardia—Dexamethasone—multiple sclerosis	0.000173	0.000518	CcSEcCtD
Ziprasidone—Angioedema—Prednisone—multiple sclerosis	0.000172	0.000517	CcSEcCtD
Ziprasidone—Dyspepsia—Triamcinolone—multiple sclerosis	0.000172	0.000514	CcSEcCtD
Ziprasidone—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000171	0.000513	CcSEcCtD
Ziprasidone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000171	0.000513	CcSEcCtD
Ziprasidone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000171	0.000513	CcSEcCtD
Ziprasidone—Vertigo—Prednisone—multiple sclerosis	0.000169	0.000508	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—multiple sclerosis	0.000169	0.000508	CcSEcCtD
Ziprasidone—Syncope—Prednisone—multiple sclerosis	0.000169	0.000507	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—multiple sclerosis	0.000169	0.000506	CcSEcCtD
Ziprasidone—Anorexia—Dexamethasone—multiple sclerosis	0.000169	0.000505	CcSEcCtD
Ziprasidone—Anorexia—Betamethasone—multiple sclerosis	0.000169	0.000505	CcSEcCtD
Ziprasidone—Urticaria—Prednisolone—multiple sclerosis	0.000168	0.000505	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—multiple sclerosis	0.000168	0.000504	CcSEcCtD
Ziprasidone—Fatigue—Triamcinolone—multiple sclerosis	0.000168	0.000504	CcSEcCtD
Ziprasidone—Fatigue—Methylprednisolone—multiple sclerosis	0.000168	0.000503	CcSEcCtD
Ziprasidone—Loss of consciousness—Prednisone—multiple sclerosis	0.000166	0.000497	CcSEcCtD
Ziprasidone—Hypotension—Dexamethasone—multiple sclerosis	0.000165	0.000496	CcSEcCtD
Ziprasidone—Hypotension—Betamethasone—multiple sclerosis	0.000165	0.000496	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—multiple sclerosis	0.000164	0.000493	CcSEcCtD
Ziprasidone—Vomiting—Mitoxantrone—multiple sclerosis	0.000164	0.000493	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—multiple sclerosis	0.000164	0.000491	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000163	0.00049	CcSEcCtD
Ziprasidone—Hypertension—Prednisone—multiple sclerosis	0.000163	0.000489	CcSEcCtD
Ziprasidone—Rash—Mitoxantrone—multiple sclerosis	0.000163	0.000488	CcSEcCtD
Ziprasidone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000163	0.000488	CcSEcCtD
Ziprasidone—Chills—Methotrexate—multiple sclerosis	0.000163	0.000487	CcSEcCtD
Ziprasidone—Headache—Mitoxantrone—multiple sclerosis	0.000162	0.000485	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000161	0.000483	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000161	0.000483	CcSEcCtD
Ziprasidone—Arthralgia—Prednisone—multiple sclerosis	0.000161	0.000482	CcSEcCtD
Ziprasidone—Myalgia—Prednisone—multiple sclerosis	0.000161	0.000482	CcSEcCtD
Ziprasidone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000161	0.000482	CcSEcCtD
Ziprasidone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00016	0.000481	CcSEcCtD
Ziprasidone—Anxiety—Prednisone—multiple sclerosis	0.00016	0.00048	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—multiple sclerosis	0.00016	0.00048	CcSEcCtD
Ziprasidone—Insomnia—Dexamethasone—multiple sclerosis	0.00016	0.00048	CcSEcCtD
Ziprasidone—Insomnia—Betamethasone—multiple sclerosis	0.00016	0.00048	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00016	0.000478	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000159	0.000477	CcSEcCtD
Ziprasidone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000159	0.000476	CcSEcCtD
Ziprasidone—Paraesthesia—Betamethasone—multiple sclerosis	0.000159	0.000476	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—multiple sclerosis	0.000159	0.000476	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—multiple sclerosis	0.000158	0.000473	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—multiple sclerosis	0.000158	0.000473	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisolone—multiple sclerosis	0.000156	0.000468	CcSEcCtD
Ziprasidone—Dyspepsia—Betamethasone—multiple sclerosis	0.000156	0.000467	CcSEcCtD
Ziprasidone—Dyspepsia—Dexamethasone—multiple sclerosis	0.000156	0.000467	CcSEcCtD
Ziprasidone—Urticaria—Triamcinolone—multiple sclerosis	0.000155	0.000464	CcSEcCtD
Ziprasidone—Urticaria—Methylprednisolone—multiple sclerosis	0.000154	0.000463	CcSEcCtD
Ziprasidone—Body temperature increased—Triamcinolone—multiple sclerosis	0.000154	0.000462	CcSEcCtD
Ziprasidone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000154	0.000461	CcSEcCtD
Ziprasidone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000154	0.000461	CcSEcCtD
Ziprasidone—Decreased appetite—Betamethasone—multiple sclerosis	0.000154	0.000461	CcSEcCtD
Ziprasidone—Nausea—Mitoxantrone—multiple sclerosis	0.000153	0.00046	CcSEcCtD
Ziprasidone—Infection—Prednisone—multiple sclerosis	0.000153	0.000459	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000153	0.000458	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000153	0.000458	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—multiple sclerosis	0.000153	0.000457	CcSEcCtD
Ziprasidone—Fatigue—Dexamethasone—multiple sclerosis	0.000152	0.000457	CcSEcCtD
Ziprasidone—Fatigue—Betamethasone—multiple sclerosis	0.000152	0.000457	CcSEcCtD
Ziprasidone—Shock—Prednisone—multiple sclerosis	0.000151	0.000454	CcSEcCtD
Ziprasidone—Nervous system disorder—Prednisone—multiple sclerosis	0.000151	0.000453	CcSEcCtD
Ziprasidone—Tachycardia—Prednisone—multiple sclerosis	0.00015	0.000451	CcSEcCtD
Ziprasidone—Skin disorder—Prednisone—multiple sclerosis	0.00015	0.000449	CcSEcCtD
Ziprasidone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000149	0.000446	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—multiple sclerosis	0.000149	0.000446	CcSEcCtD
Ziprasidone—Anorexia—Prednisone—multiple sclerosis	0.000147	0.00044	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—multiple sclerosis	0.000146	0.000437	CcSEcCtD
Ziprasidone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000146	0.000437	CcSEcCtD
Ziprasidone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000146	0.000437	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000145	0.000434	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000145	0.000434	CcSEcCtD
Ziprasidone—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000144	0.000431	CcSEcCtD
Ziprasidone—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000143	0.00043	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—multiple sclerosis	0.000142	0.000425	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—multiple sclerosis	0.000141	0.000423	CcSEcCtD
Ziprasidone—Urticaria—Dexamethasone—multiple sclerosis	0.00014	0.000421	CcSEcCtD
Ziprasidone—Urticaria—Betamethasone—multiple sclerosis	0.00014	0.000421	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00014	0.000421	CcSEcCtD
Ziprasidone—Dizziness—Prednisolone—multiple sclerosis	0.00014	0.00042	CcSEcCtD
Ziprasidone—Asthenia—Triamcinolone—multiple sclerosis	0.00014	0.000419	CcSEcCtD
Ziprasidone—Body temperature increased—Dexamethasone—multiple sclerosis	0.00014	0.000419	CcSEcCtD
Ziprasidone—Abdominal pain—Dexamethasone—multiple sclerosis	0.00014	0.000419	CcSEcCtD
Ziprasidone—Body temperature increased—Betamethasone—multiple sclerosis	0.00014	0.000419	CcSEcCtD
Ziprasidone—Abdominal pain—Betamethasone—multiple sclerosis	0.00014	0.000419	CcSEcCtD
Ziprasidone—Asthenia—Methylprednisolone—multiple sclerosis	0.000139	0.000418	CcSEcCtD
Ziprasidone—Insomnia—Prednisone—multiple sclerosis	0.000139	0.000418	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisone—multiple sclerosis	0.000138	0.000415	CcSEcCtD
Ziprasidone—Cough—Methotrexate—multiple sclerosis	0.000138	0.000413	CcSEcCtD
Ziprasidone—Dyspepsia—Prednisone—multiple sclerosis	0.000136	0.000407	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—multiple sclerosis	0.000134	0.000403	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—multiple sclerosis	0.000134	0.000403	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—multiple sclerosis	0.000134	0.000403	CcSEcCtD
Ziprasidone—Decreased appetite—Prednisone—multiple sclerosis	0.000134	0.000401	CcSEcCtD
Ziprasidone—Rash—Prednisolone—multiple sclerosis	0.000134	0.000401	CcSEcCtD
Ziprasidone—Dermatitis—Prednisolone—multiple sclerosis	0.000133	0.0004	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000133	0.0004	CcSEcCtD
Ziprasidone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000133	0.000399	CcSEcCtD
Ziprasidone—Fatigue—Prednisone—multiple sclerosis	0.000133	0.000398	CcSEcCtD
Ziprasidone—Headache—Prednisolone—multiple sclerosis	0.000133	0.000398	CcSEcCtD
Ziprasidone—Constipation—Prednisone—multiple sclerosis	0.000132	0.000395	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—multiple sclerosis	0.00013	0.000389	CcSEcCtD
Ziprasidone—Dizziness—Triamcinolone—multiple sclerosis	0.000129	0.000386	CcSEcCtD
Ziprasidone—Dizziness—Methylprednisolone—multiple sclerosis	0.000129	0.000386	CcSEcCtD
Ziprasidone—Infection—Methotrexate—multiple sclerosis	0.000128	0.000383	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisone—multiple sclerosis	0.000127	0.000381	CcSEcCtD
Ziprasidone—Asthenia—Dexamethasone—multiple sclerosis	0.000127	0.00038	CcSEcCtD
Ziprasidone—Asthenia—Betamethasone—multiple sclerosis	0.000127	0.00038	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—multiple sclerosis	0.000126	0.000378	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000126	0.000378	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000126	0.000378	CcSEcCtD
Ziprasidone—Nausea—Prednisolone—multiple sclerosis	0.000126	0.000377	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—multiple sclerosis	0.000125	0.000375	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000124	0.000373	CcSEcCtD
Ziprasidone—Vomiting—Triamcinolone—multiple sclerosis	0.000124	0.000372	CcSEcCtD
Ziprasidone—Vomiting—Methylprednisolone—multiple sclerosis	0.000124	0.000371	CcSEcCtD
Ziprasidone—Rash—Triamcinolone—multiple sclerosis	0.000123	0.000368	CcSEcCtD
Ziprasidone—Dermatitis—Triamcinolone—multiple sclerosis	0.000123	0.000368	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—multiple sclerosis	0.000123	0.000368	CcSEcCtD
Ziprasidone—Rash—Methylprednisolone—multiple sclerosis	0.000123	0.000368	CcSEcCtD
Ziprasidone—Dermatitis—Methylprednisolone—multiple sclerosis	0.000122	0.000367	CcSEcCtD
Ziprasidone—Urticaria—Prednisone—multiple sclerosis	0.000122	0.000367	CcSEcCtD
Ziprasidone—Headache—Triamcinolone—multiple sclerosis	0.000122	0.000366	CcSEcCtD
Ziprasidone—Headache—Methylprednisolone—multiple sclerosis	0.000122	0.000365	CcSEcCtD
Ziprasidone—Body temperature increased—Prednisone—multiple sclerosis	0.000122	0.000365	CcSEcCtD
Ziprasidone—Abdominal pain—Prednisone—multiple sclerosis	0.000122	0.000365	CcSEcCtD
Ziprasidone—Diarrhoea—Betamethasone—multiple sclerosis	0.000121	0.000363	CcSEcCtD
Ziprasidone—Diarrhoea—Dexamethasone—multiple sclerosis	0.000121	0.000363	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—multiple sclerosis	0.00012	0.000361	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000117	0.000352	CcSEcCtD
Ziprasidone—Dizziness—Dexamethasone—multiple sclerosis	0.000117	0.000351	CcSEcCtD
Ziprasidone—Dizziness—Betamethasone—multiple sclerosis	0.000117	0.000351	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—multiple sclerosis	0.000116	0.000349	CcSEcCtD
Ziprasidone—Nausea—Triamcinolone—multiple sclerosis	0.000116	0.000347	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—multiple sclerosis	0.000116	0.000347	CcSEcCtD
Ziprasidone—Nausea—Methylprednisolone—multiple sclerosis	0.000115	0.000346	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—multiple sclerosis	0.000115	0.000344	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—multiple sclerosis	0.000114	0.000343	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisone—multiple sclerosis	0.000113	0.00034	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—multiple sclerosis	0.000113	0.00034	CcSEcCtD
Ziprasidone—Vomiting—Betamethasone—multiple sclerosis	0.000112	0.000337	CcSEcCtD
Ziprasidone—Vomiting—Dexamethasone—multiple sclerosis	0.000112	0.000337	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—multiple sclerosis	0.000112	0.000335	CcSEcCtD
Ziprasidone—Rash—Dexamethasone—multiple sclerosis	0.000111	0.000334	CcSEcCtD
Ziprasidone—Rash—Betamethasone—multiple sclerosis	0.000111	0.000334	CcSEcCtD
Ziprasidone—Dermatitis—Dexamethasone—multiple sclerosis	0.000111	0.000334	CcSEcCtD
Ziprasidone—Dermatitis—Betamethasone—multiple sclerosis	0.000111	0.000334	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000111	0.000333	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—multiple sclerosis	0.000111	0.000333	CcSEcCtD
Ziprasidone—Headache—Dexamethasone—multiple sclerosis	0.000111	0.000332	CcSEcCtD
Ziprasidone—Headache—Betamethasone—multiple sclerosis	0.000111	0.000332	CcSEcCtD
Ziprasidone—Asthenia—Prednisone—multiple sclerosis	0.00011	0.000331	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—multiple sclerosis	0.000106	0.000318	CcSEcCtD
Ziprasidone—Diarrhoea—Prednisone—multiple sclerosis	0.000105	0.000316	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000105	0.000316	CcSEcCtD
Ziprasidone—Nausea—Betamethasone—multiple sclerosis	0.000105	0.000315	CcSEcCtD
Ziprasidone—Nausea—Dexamethasone—multiple sclerosis	0.000105	0.000315	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—multiple sclerosis	0.000102	0.000307	CcSEcCtD
Ziprasidone—Dizziness—Prednisone—multiple sclerosis	0.000102	0.000305	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—multiple sclerosis	0.000102	0.000305	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—multiple sclerosis	0.000102	0.000305	CcSEcCtD
Ziprasidone—Vomiting—Prednisone—multiple sclerosis	9.79e-05	0.000294	CcSEcCtD
Ziprasidone—Rash—Prednisone—multiple sclerosis	9.71e-05	0.000291	CcSEcCtD
Ziprasidone—Dermatitis—Prednisone—multiple sclerosis	9.7e-05	0.000291	CcSEcCtD
Ziprasidone—Headache—Prednisone—multiple sclerosis	9.65e-05	0.000289	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—multiple sclerosis	9.48e-05	0.000284	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—multiple sclerosis	9.23e-05	0.000277	CcSEcCtD
Ziprasidone—Nausea—Prednisone—multiple sclerosis	9.15e-05	0.000274	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—multiple sclerosis	8.8e-05	0.000264	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—multiple sclerosis	8.51e-05	0.000255	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—multiple sclerosis	8.18e-05	0.000245	CcSEcCtD
Ziprasidone—Rash—Methotrexate—multiple sclerosis	8.11e-05	0.000243	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—multiple sclerosis	8.11e-05	0.000243	CcSEcCtD
Ziprasidone—Headache—Methotrexate—multiple sclerosis	8.06e-05	0.000242	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—multiple sclerosis	7.64e-05	0.000229	CcSEcCtD
Ziprasidone—HTR1D—Signaling Pathways—IL2—multiple sclerosis	9.76e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	9.76e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MAPK1—multiple sclerosis	9.75e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—APOE—multiple sclerosis	9.73e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	9.71e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	9.7e-06	4.46e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	9.69e-06	4.46e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	9.64e-06	4.43e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	9.59e-06	4.41e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL2—multiple sclerosis	9.56e-06	4.4e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	9.53e-06	4.39e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	9.51e-06	4.38e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	9.43e-06	4.34e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL2—multiple sclerosis	9.41e-06	4.33e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	9.38e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	9.38e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—IL6—multiple sclerosis	9.36e-06	4.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	9.33e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MMP9—multiple sclerosis	9.31e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MMP9—multiple sclerosis	9.3e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL2—multiple sclerosis	9.28e-06	4.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—POMC—multiple sclerosis	9.26e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	9.24e-06	4.25e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—IL6—multiple sclerosis	9.23e-06	4.25e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—ALB—multiple sclerosis	9.2e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	9.18e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	9.12e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CD80—multiple sclerosis	9.1e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	9.07e-06	4.17e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	9.05e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	9.01e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	8.98e-06	4.13e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CD80—multiple sclerosis	8.96e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CD80—multiple sclerosis	8.94e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CD80—multiple sclerosis	8.91e-06	4.1e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MMP9—multiple sclerosis	8.9e-06	4.1e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL2—multiple sclerosis	8.89e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CD80—multiple sclerosis	8.88e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—IL6—multiple sclerosis	8.84e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CD80—multiple sclerosis	8.79e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MMP9—multiple sclerosis	8.78e-06	4.04e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	8.77e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	8.75e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	8.71e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—POMC—multiple sclerosis	8.65e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—POMC—multiple sclerosis	8.51e-06	3.92e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—POMC—multiple sclerosis	8.49e-06	3.91e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—POMC—multiple sclerosis	8.48e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	8.47e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL2—multiple sclerosis	8.47e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—IL6—multiple sclerosis	8.46e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—POMC—multiple sclerosis	8.46e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCL2—multiple sclerosis	8.46e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—ALB—multiple sclerosis	8.44e-06	3.88e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—POMC—multiple sclerosis	8.44e-06	3.88e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—IL6—multiple sclerosis	8.43e-06	3.88e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MMP9—multiple sclerosis	8.41e-06	3.87e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL2—multiple sclerosis	8.35e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—POMC—multiple sclerosis	8.35e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	8.33e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	8.33e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	8.33e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—IL6—multiple sclerosis	8.31e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCL2—multiple sclerosis	8.31e-06	3.82e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	8.28e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	8.28e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—STAT3—multiple sclerosis	8.28e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—STAT3—multiple sclerosis	8.27e-06	3.8e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	8.25e-06	3.8e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	8.21e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	8.17e-06	3.76e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	8.15e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	8.15e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	8.15e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	8.13e-06	3.74e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	8.1e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	8.08e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	8.04e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MMP9—multiple sclerosis	8.01e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	8e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	7.98e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—STAT3—multiple sclerosis	7.92e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MMP9—multiple sclerosis	7.91e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—STAT3—multiple sclerosis	7.81e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	7.74e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ALB—multiple sclerosis	7.73e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MYC—multiple sclerosis	7.69e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MYC—multiple sclerosis	7.68e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TYK2—multiple sclerosis	7.68e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	7.67e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TGFB1—multiple sclerosis	7.66e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MYC—multiple sclerosis	7.63e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.63e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	7.61e-06	3.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	7.57e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	7.56e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TYK2—multiple sclerosis	7.54e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	7.54e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	7.52e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	7.52e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MAPK1—multiple sclerosis	7.52e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	7.51e-06	3.45e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	7.5e-06	3.45e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—IL6—multiple sclerosis	7.49e-06	3.45e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—STAT3—multiple sclerosis	7.48e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MYC—multiple sclerosis	7.47e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	7.47e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	7.46e-06	3.43e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	7.42e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	7.41e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	7.4e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MYC—multiple sclerosis	7.35e-06	3.38e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	7.34e-06	3.38e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	7.31e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL2—multiple sclerosis	7.28e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MYC—multiple sclerosis	7.26e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	7.25e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL2—multiple sclerosis	7.24e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TGFB1—multiple sclerosis	7.24e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	7.21e-06	3.32e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	7.2e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	7.14e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—STAT3—multiple sclerosis	7.13e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MAPK1—multiple sclerosis	7.1e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	7.05e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—STAT3—multiple sclerosis	7.03e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—APOE—multiple sclerosis	7.02e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	7.01e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MYC—multiple sclerosis	6.95e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	6.93e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TGFB1—multiple sclerosis	6.93e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	6.9e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	6.89e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	6.88e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	6.86e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MAPK1—multiple sclerosis	6.8e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	6.67e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MYC—multiple sclerosis	6.62e-06	3.05e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	6.61e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	6.56e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MYC—multiple sclerosis	6.53e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	6.52e-06	3e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	6.48e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—multiple sclerosis	6.39e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	6.39e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—multiple sclerosis	6.36e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	6.35e-06	2.92e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—multiple sclerosis	6.29e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—multiple sclerosis	6.28e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	6.26e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—multiple sclerosis	6.26e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—multiple sclerosis	6.25e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—multiple sclerosis	6.24e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	6.23e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	6.21e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—multiple sclerosis	6.18e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	6.16e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	6.15e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	6.13e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	6.13e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	6.1e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—multiple sclerosis	6.05e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—POMC—multiple sclerosis	6.03e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	5.95e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—APOE—multiple sclerosis	5.95e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—multiple sclerosis	5.94e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	5.93e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	5.92e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	5.9e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	5.9e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	5.88e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	5.85e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	5.84e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	5.83e-06	2.68e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—multiple sclerosis	5.78e-06	2.66e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—multiple sclerosis	5.78e-06	2.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	5.77e-06	2.66e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—multiple sclerosis	5.74e-06	2.64e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	5.72e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	5.69e-06	2.62e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—multiple sclerosis	5.69e-06	2.62e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	5.68e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—multiple sclerosis	5.66e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	5.65e-06	2.6e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—multiple sclerosis	5.62e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	5.57e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	5.54e-06	2.55e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—multiple sclerosis	5.53e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	5.51e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—multiple sclerosis	5.5e-06	2.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	5.5e-06	2.53e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—multiple sclerosis	5.45e-06	2.51e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	5.42e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	5.42e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	5.41e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	5.39e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—multiple sclerosis	5.38e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	5.3e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	5.29e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—multiple sclerosis	5.28e-06	2.43e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	5.27e-06	2.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	5.25e-06	2.41e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—multiple sclerosis	5.22e-06	2.4e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	5.2e-06	2.39e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	5.18e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—POMC—multiple sclerosis	5.11e-06	2.35e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—multiple sclerosis	5e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	4.99e-06	2.29e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—multiple sclerosis	4.98e-06	2.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—multiple sclerosis	4.92e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—multiple sclerosis	4.91e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—multiple sclerosis	4.91e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	4.91e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	4.9e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—multiple sclerosis	4.89e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	4.89e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	4.88e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—multiple sclerosis	4.88e-06	2.24e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	4.87e-06	2.24e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—multiple sclerosis	4.83e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	4.82e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	4.82e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	4.82e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	4.81e-06	2.21e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	4.8e-06	2.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	4.8e-06	2.21e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	4.79e-06	2.2e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	4.77e-06	2.2e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	4.72e-06	2.17e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	4.71e-06	2.17e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—multiple sclerosis	4.66e-06	2.14e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOE—multiple sclerosis	4.59e-06	2.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	4.48e-06	2.06e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	4.46e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	4.43e-06	2.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	4.38e-06	2.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—multiple sclerosis	4.28e-06	1.97e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—multiple sclerosis	4.26e-06	1.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	4.14e-06	1.91e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	4.08e-06	1.88e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—POMC—multiple sclerosis	3.94e-06	1.81e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—multiple sclerosis	3.76e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—multiple sclerosis	3.7e-06	1.7e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—multiple sclerosis	3.69e-06	1.7e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—multiple sclerosis	3.68e-06	1.69e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—multiple sclerosis	3.67e-06	1.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—multiple sclerosis	3.63e-06	1.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	3.62e-06	1.67e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—multiple sclerosis	3.6e-06	1.65e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	3.36e-06	1.55e-05	CbGpPWpGaD
